Mereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) shares fell 2.6% on Thursday . The stock traded as low as $3.65 and last traded at $3.71. 174,809 shares traded hands during trading, a decline of 79% from the average session volume of 830,890 shares. The stock had previously closed at $3.81.
MREO has been the topic of several research analyst reports. Lifesci Capital initiated coverage on Mereo BioPharma Group in a report on Tuesday. They issued an "outperform" rating and a $10.00 price objective on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $7.00 price target on shares of Mereo BioPharma Group in a research note on Tuesday, November 12th. Cantor Fitzgerald raised Mereo BioPharma Group to a "strong-buy" rating in a research note on Sunday, December 8th. Finally, Jefferies Financial Group assumed coverage on shares of Mereo BioPharma Group in a report on Friday, December 6th. They set a "buy" rating and a $7.00 target price for the company. Four investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $7.83.
Get Our Latest Stock Report on MREO
The firm has a fifty day moving average price of $3.85 and a 200 day moving average price of $4.02.
Several hedge funds have recently made changes to their positions in the company. Frazier Life Sciences Management L.P. acquired a new position in Mereo BioPharma Group in the second quarter valued at approximately $15,845,000. Integral Health Asset Management LLC raised its position in Mereo BioPharma Group by 86.8% in the second quarter. Integral Health Asset Management LLC now owns 1,775,000 shares of the company's stock valued at $6,390,000 after purchasing an additional 825,000 shares during the period. Rubric Capital Management LP lifted its stake in shares of Mereo BioPharma Group by 12.9% in the 2nd quarter. Rubric Capital Management LP now owns 15,307,347 shares of the company's stock valued at $55,106,000 after purchasing an additional 1,754,350 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new position in shares of Mereo BioPharma Group during the 2nd quarter worth $24,158,000. Finally, Millennium Management LLC increased its position in shares of Mereo BioPharma Group by 46.9% during the 2nd quarter. Millennium Management LLC now owns 3,201,705 shares of the company's stock worth $11,526,000 after purchasing an additional 1,022,570 shares during the last quarter. Hedge funds and other institutional investors own 62.83% of the company's stock.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mereo BioPharma Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mereo BioPharma Group wasn't on the list.
While Mereo BioPharma Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.